您现在的位置: 首页> 研究主题> T细胞增殖

T细胞增殖

T细胞增殖的相关文献在1990年到2022年内共计1861篇,主要集中在基础医学、药学、内科学 等领域,其中期刊论文84篇、会议论文8篇、专利文献107953篇;相关期刊62种,包括生物技术通报、微生物学报、中国实验动物学报等; 相关会议7种,包括2015年第十三届全国风湿病学术会议、第十三届中南地区实验动物科技交流会、第五届全军器官移植学术会议等;T细胞增殖的相关文献由3810位作者贡献,包括孙波、不公告发明人、权栋栋等。

T细胞增殖—发文量

期刊论文>

论文:84 占比:0.08%

会议论文>

论文:8 占比:0.01%

专利文献>

论文:107953 占比:99.91%

总计:108045篇

T细胞增殖—发文趋势图

T细胞增殖

-研究学者

  • 孙波
  • 不公告发明人
  • 权栋栋
  • 王洪涛
  • 杨志华
  • 刘艳辉
  • 李晶
  • 权威宇
  • 胡乃合
  • 朱立平
  • 期刊论文
  • 会议论文
  • 专利文献

搜索

排序:

年份

作者

    • 李菲; 万龙; 姜明燕
    • 摘要: 目的 探讨补骨脂乙醇提取物(PCEE)对人T细胞亚群增殖和活化的影响.方法 采集健康人EDTA抗凝血,分离外周血单个核细胞(PBMCs),ADD染色流式细胞术检测PCEE(1、2mg/mL)对PBMCs的毒性;PBMCs分为对照组、模型组、PCEE(1 mg/mL)组,模型组和PCEE组用植物血凝素(PHA)5 μg/mL刺激,对照组不加;3 d后PCEE组加入终质量浓度为1mg/mL的PCEE作用48h,对照组和模型加入等体积的PBS.48h后收集细胞,用流式细胞术检测CD4+和CD8+T细胞亚群增殖(ADD染色)、活化(CD69和CD25)以及AKT、NF-κB磷酸化水平.结果 PCEE 1 mg/mL组活细胞比例为(93.06+2.12)%,与对照组(95.16±1.39)%比较无显著差别;PCEE组CD4+和CD8+T细胞的增殖显著低于模型组(P<0.001);PCEE 组 CD69+CD4+、CD69+CD8+和 CD25+CD4+、CD25+CD8+T 细胞比例显著低于模型组(P<0.05);PCEE 组pAKT+CD4+、pAKT+CD8+和pNF-κB+CD4+、pNF-κB+CD8+T细胞比例显著低于模型组(P<0.05).结论 补骨脂通过抑制AKT/NF-κB信号传导通路显著抑制T细胞增殖和活化.
    • 吴利红; 杨淑霞; 邓弘仙; 张云惠; 黄玲; 范诗逸; 蒋海静; 赖翼; 罗兴燕; 刘阳
    • 摘要: 目的 探究伪石蒜碱抑制活化T细胞增殖与功能的机制.方法 密度梯度离心法和免疫磁珠法分离纯化T细胞,抗CD3/CD28或植物凝集素(phytohemagglutinin,PHA)活化T细胞.流式细胞术检测细胞增殖、细胞凋亡、CD25表达及细胞周期;ELISA检测细胞因子IL-2、IL-6、IL-17A、IFN-γ的分泌水平.结果 伪石蒜碱抑制抗CD3/CD28或PHA活化T细胞增殖,IC50分别为(0.97±0.22) μmol·L-1和(0.82±0.07) μmol·L-1.在完全抑制活化T细胞增殖的浓度下,伪石蒜碱不诱导活化T细胞凋亡,且不对静息T细胞的细胞活力产生显著影响.伪石蒜碱不影响活化T细胞表达CD25和分泌IL-2,但阻滞细胞周期于G0/G1期.伪石蒜碱显著抑制IL-6、IL-17A、IFN-γ的分泌.结论 伪石蒜碱不影响T细胞的活化,但通过阻滞细胞周期于G0/G1期抑制活化T细胞的增殖,提示伪石蒜碱有望成为先导化合物用于开发新型免疫抑制剂.
    • 唐苗; 余万鑫; 吴桃清; 马秀英; 刘衡; 张成桂; 白丽; 肖怀
    • 摘要: Aim To investigate the effects of Periplane-ta americana extract Ento-A on the immune function in immunosuppressed mice . Methods Immunosup-pressed mouse model was induced by intraperitoneal injection of cyclophosphamide in KM mice .To evalu-ate the effects of Ento-A on the immune function in im-munosuppressed mice , neutral red method and MTT assay were used respectively to detect the effects of En-to-A on the phagocytosis of peritoneal macrophages and T cell proliferation rate in mice; with sheep red blood cell as immunogen , the effects of Ento-A on the pro-duction of serum hemolysin were evaluated;peripheral blood was tested and immune organ index calculated . Results Compared with model control group , the high, medium and low doses of Ento-A could improve the expression of serum hemolysin in immunosup-pressed mice ( P0.05), signifi-cantly increased the content of WBC ( P0.05 ) in peripheral blood , significantly enhanced phagocytic function and T lymphocyte proliferative abil-ity in a dose-dependent manner ( P0.05),明显增加外周血象中WBC(P0.05),明显增强腹腔巨噬细胞的吞噬功能及T淋巴细胞增殖能力(P<0.01),且呈剂量依赖性.结论 美洲大蠊提取物Ento-A对免疫抑制小鼠的免疫功能有增强作用.
    • 王思雨; 熊静; 周宏; 罗兴燕; 刘阳; 赖翼
    • 摘要: 目的 探究PO-291抑制活化T细胞增殖与功能的机制.方法 免疫磁珠法纯化人外周血T细胞,抗CD3/ CD28抗体或同种异型抗原活化T细胞.流式细胞术检测细胞增殖、细胞凋亡、细胞活力、CD25和CD69表达以及细胞周期;ELISA检测细胞因子 IL-2、 IL-4、 IL-6、 IL-10、 IL-17 和 IFN-γ的分泌水平;蛋白免疫印迹检测STAT5与p70S6K的表达和磷酸化.结果 PO-291抑制抗CD3/CD28抗体或同种异型抗原活化的 T 细胞增殖,IC50分别为(8.09 ± 1.04) μmol· L-1、(8.01 ± 0.95) μmol·L-1.在完全抑制活化T细胞增殖的浓度下,PO-291不诱导T细胞凋亡,且在浓度达到160 μmol·L-1时,不影响静息 T 细胞和 PBMC 的细胞存活.PO-291不影响活化T细胞表达CD25、CD69和分泌IL-2,但阻滞T细胞周期于G0/G1期. PO-291不影响IL-2、IL-4、IL-10,但明显抑制 IFN-γ、IL-6、IL-17 的分泌. PO-291 不影响STAT5 和 p70S6K 表达,但抑制 STAT5 磷酸化,且可增强p70S6K磷酸化.结论 PO-291通过阻断JAK3/STAT5信号通路,抑制活化T细胞增殖,提示PO-291有望成为先导化合物,为开发用于器官移植以及自身免疫性疾病的新型药物提供新的方向.%Objective To investigate the immunosup-pressive activity of benzoxazole derivative PO-291 in inhibiting human activated T cell proliferation and function. Methods Human T cells were isolated and purified by the immunomagnetic microbeads and acti-vated by anti-CD3/anti-CD28 mAbs or alloantigen. Cell proliferation, the expression of CD25 and CD69, cell cycle and apoptosis were measured by flow cytome-try. Secretion levels, including IL-2, IL-4, IL-6, IL-10, IL-17 and IFN-γ were determined by ELISA. The expression and phosphorylation of STAT5 and p70S6K of activated T cells were detected by Western blot. Re-sults PO-291 significantly inhibited human T cell proliferation with anti-CD3/anti-CD28 mAbs or alloan-tigen stimulation without obvious cytotoxicity. PO-291 did not affect CD25, CD69 and IL-2 expression, but induced T cell cycle arrest in G0/G1 phase. PO-291 significantly inhibited IL-17, IFN-γ and IL-6 expres-sion, but not IL-2, IL-4 and IL-10. PO-291 did not affect STAT5 and p70S6K expression, but inhibited STAT5 phosphorylation and enhanced p70S6K phos-phorylation. Conclusions PO-291 inhibits human ac-tivated T cell proliferation by affecting the JAK3/STAT5 pathway. PO-291 represents a potential lead compound for the design and development of new im-munosuppressive drugs for the treatment of organ trans-plantation and autoimmune diseases.
    • 贾敏; 张卉; 童亚林; 姚咏明
    • 摘要: Objective:To investigate the inhibitory effect of high mobility group box-1 protein (HMGB1) on T cell proliferation and the regulation mechanisms thereof.Methods:Cultured Jurkat cells were divided into 4 groups:control group,HMGB1 treatment (100 ng/ml) for 12,24 and 48 hours groups.Cells were also divided into control group,10,100 and 1 000 ng/ml HMGB1 treated groups,and then stimulated for 24 hours.Proliferation rates of cells were measured using cell counting kit (CCK-8).The expression levels of p53 mRNA,phosphorylated p53 and p53 protein were determined by real-time polymerase chain reaction (RT-PCR) and Western blot respectively.Jurkat cells were transfected with lentivirus containing p53 shRNA,p53 mRNA sequence expressing plasmids or control vector.The cells were afterwards stimulated with HMGB1 (100 ng/ml) for 24 hours,and subjected to cell proliferation assay with the same methods mentioned above.In addition,Jurkat cells were divided into 3 groups:control group,HMGB1 group and HMGB1+SB203580 group,and stimulated with indicated reagents for 24 hours.The expression levels of p53 mRNA,phosphorylated p53 and p53 protein were detected by RT-PCR and Western blot.Results:Compared to the control group,the proliferation rates of cells were decreased after HMGB1 (100 ng/ml) stimulation for 24 and 48 hours (P<0.05).In dose-dependent stimulations,proliferation rates were reduced in treatment with 100 or 1 000 ng/ml HMGB1 groups (P<0.05).The expression levels of p53 mRNA,phosphorylated p53 and p53 protein increased in cells after stimulation with 100 ng/ml HMGB1 for 24 and 48 hours (P<0.05).The expression levels increased obviously in 10 and 100 ng/ml HMGB1 treated cells 24 hours later,but the level was not changed significantly in HMGB1 1 000 ng/ml group.After transfection,the proliferation rates of vector-expressing cells decreased obviously after HMGB1 stimulation.The proliferation of p53 shRNA-expressing cells was basically normal,while of p53 mRNA over expression cells showed lower proliferation rate comparing to vector group (P<0.05).Treatment with p38 MAPK inhibitor (SB203580) and HMGB1 markedly down-regulated the expression levels of p53 mRNA,phosphorylated and total p53 protein (P<0.05).Conclusion:Extracellular HMGB1 may inhibit the proliferation of T cells by activation of p53 through p38 MAPK pathway.%目的:探讨高迁移率蛋白族B1 (HMGB1)对T细胞的增殖抑制作用及其分子机制.方法:将培养的Jurkat细胞分为对照组、HMGB1 (100 ng/ml) 12、24、48 h组,HMGB1组加入HMGB1培养相应时间;将细胞分为对照组、HMGB1 10、100、1 000 ng/ml组,予不同浓度HMGB1培养24 h;采用细胞计数试剂盒(CCK-8)法检测各组细胞增殖率,采用实时荧光定量-聚合酶链反应(RT-PCR)和Western blot法检测各组细胞中p53mRNA、磷酸化p53及p53总蛋白的表达水平.将载有p53 shRNA、p53 mRNA表达序列及空白质料的病毒转染入Jurkat细胞中,并选择100 ng/ml HMGB1刺激24 h,采用同样方法检测细胞增殖率.最后,将细胞分为正常组、HMGB1组、SB203580[p38丝裂原活化蛋白激酶(p38MAPK)抑制剂]+HMGB1组进行相应处理.收集各组细胞,RT-PCR和Western blot法检测p53 mRNA、磷酸化p53及p53总蛋白的表达水平.结果:HMGBl (100ng/ml)刺激细胞24、48 h后细胞增殖率降低,较正常组差异有显著性(P<0.05);100、l 000 ng/ml HMGB1刺激细胞24 h后,增殖率明显下降,与正常组相比差异具有统计学意义(P<0.05).HMGB1 (100 ng/ml)刺激细胞后,p53 mRNA、磷酸化及总蛋白表达水平在24、48 h逐步上升,且有明显统计学意义(P<0.05);HMGB1刺激24 h,10、100 ng/ml HMGB1刺激组细胞p53 mRNA、p53磷酸化及总蛋白表达水平较正常组显著上升,但1 000 ng/mlHMGB1没有明显变化;在不同转染组中,予HMGB1刺激细胞,空载组增殖率降低,而p53 shRNA表达组细胞增殖趋于正常,p53 mRNA过表达组增殖率较空载组下降更为明显.Jurkat细胞在p38 MAPK阻断剂和HMGB1共同作用后,p53 mRNA、磷酸化及总蛋白表达水平比HMGB1刺激组明显下降(P<0.05).结论:胞外HMGB1可通过诱导p38 MAPK信号通路激活p53蛋白,抑制T细胞增殖.
    • 赖翼; 罗兴燕; 夏超亚; 周宏; 吴秀银; 樊苗; 郭慧杰; 莫春芬; 邹强; 刘阳
    • 摘要: 目的:细胞高通量筛选发现苯并噻唑衍生物BD960具有免疫抑制活性,文中探讨BD960抑制T细胞增殖的作用机制。方法免疫磁珠纯化人外周血T 细胞,Anti-CD3/CD28mAbs 或同种异型抗原活化 T细胞。流式细胞术检测BD960对活化T细胞的增殖抑制作用、静息T细胞的细胞毒性作用、CD25表达及细胞周期。酶联免疫吸附法测定BD960对活化T细胞分泌IL-2、IL-4、IL-6、IL-10、IL-17A及IFN-γ等细胞因子的影响。结果 BD960抑制Anti-CD3/CD28 mAbs或同种异型抗原刺激的T细胞增殖,IC50分别为(2.3±0.3)μmol/L和(2.5±0.3)μmol/L,且浓度达100μmol/L也不影响静息T细胞和PBMC的存活。 Anti-CD3/CD28 mAbs刺激T细胞72 h表达的CD25比为69.7%,BD960在(0.625、2.5、10)μmol/L均不抑制活化T细胞表达CD25,而0.1μmol/L FK506可抑制CD25表达低至9.4%。活化96 h的T细胞,G0/G1期细胞比为58.5%。 BD960能阻滞细胞周期于G0/G1期,并随着浓度的提高G0/G1比例增大。 BD960在(0.625、2.5、10)μmol/L能抑制活化T细胞分泌IFN-γ、IL-6和IL-17并呈剂量依赖效应,但不影响IL-2、IL-4和IL-10。结论 BD960抑制作用在T细胞增殖为细胞活化的后期,同时抑制IL-6、IL-17A和IFN-γ等促炎细胞因子的分泌,抑制作用不同于FK506。 BD960有望作为先导化合物开发新型免疫抑制剂。%Objective Benzothiazole derivative BD960 has immunosuppressive activity after cell -based assays for high-throughput screening.The paper aimed to investigate the involved mechanism of BD960 on T cell proliferation. Methods Human peripheral blood T-lymphocytes were isolated and purified by the immunomagnetic microbeads.Then the T cells were activated by anti-CD3/anti-CD28 mAbs or alloantigen.The effect of BD960 on activa-ted T cell proliferation, the cytotoxic effect BD960 on resting T cells and the expression of activated T cells marker CD25 were measured by flow cytometer.Cytokine levels, including IL-2, IL-4, IL-6, IL-10, IL-17A and IFN-γ, were determined by ELISA. Results BD960 significantly inhibited the proliferation of T cells stimulated by anti-CD3/anti-CD28 mAb or alloantigen in a dose-dependent manner.The IC50 value is (2.3 ±0.3)μmol/L or (2.5 ±0.3)μmol/L, respectively.Moreover, BD960 had no obvious cytotoxic effects on rest-ing T cells and peripheral blood mononuclear cells, even at a high concentration ( up to 100μmol/L) .The ratio of CD25 expression on T cell was 69.7%after stimulated by Anti-CD3/CD28 mAbs with 72 h, the concentration (0.625、2.5、10)μmol/L of BD960 also had no potent effects on the ratio, but 0.1μmol/L FK506 could inhibit CD25 expression as low as 9.4%.The G0/G1 phase of activated T cells was 58.5%after stimulated by BD960 with 96 h.BD960 could induce cell cycle arrest at the G0/G1 phase in activated T cells with the increase of concentration and RAPA in the concentration of 0.1 μmol/L was 91.5%.In addition, BD960 (0.625、2.5、10)μmol/L could inhibit the secretion of IFN-γ, IL-6 and IL-17 in activated T cells with the increase of concentration, without any effects on the secretion of IL-2, IL-4 and IL-10. Conclusion BD960 not only exerts the inhibition on the late stage of T cell activation of cell proliferation but also inhibits the secretion of inflammatory cytokines, such as IL-6, IL-17 and IFN-γ, while the mechanism of BD960 on T cell proliferation was not the same as FK506.As a result, BD960 has the potential to be the lead compound to develop a new immunosuppressant.
    • 罗兴燕; 邹强; 孙海; 胡松; 唐信威; 何莉; 夏超亚; 王茂田; 刘阳
    • 摘要: 目的 探讨新型苯并噻唑衍生物BD759抑制T细胞增殖的作用机制.方法 流式细胞术检测T细胞增殖、CD25表达及细胞周期.酶联免疫吸附法测定BD759对活化T细胞分泌白细胞介素-2、白细胞介素-4、白细胞介素-6、白细胞介素-10、白细胞介素-17A及干扰素-γ等细胞因子的影响.结果 BD759抑制抗人CD3和CD28mAbs刺激的T细胞增和混合淋巴细胞反应,IC50分别为(3.5±0.7)和(3.3±0.9) μmol·L-1.BD759对人静息T细胞和外周血单个核细胞无细胞毒性.BD759不抑制活化的T细胞表达CD25和分泌细胞因子白细胞介素-2、白细胞介素-4及白细胞介素-10,但显著抑制白细胞介素-6、白细胞介素-17A和干扰素-γ的产生,并且阻滞细胞周期于G0/G1期.结论 新型苯并噻唑衍生物BD759不影响T细胞的活化,但通过阻滞细胞周期于G0/G1期抑制活化的T细胞增殖,并抑制白细胞介素-6、白细胞介素-17A和干扰素-γ等促炎细胞因子的分泌.BD759有望作为先导化合物,开发用于自身免疫性疾病与器官移植的新型药物.
    • 孙海; 邹强; 莫春芬; 罗兴燕; 郭慧杰; 胡松; 唐信威; 樊苗; 赖翼; 刘阳
    • 摘要: Obej ctive Abnormal proliferation of T cells plays an important role in the development of autoimmune diseases. The article aimed to study the inhibitory effect of small molecule compound BD691 on T cell proliferation and its mechanism. Methods Human peripheral blood T-lymphocytes were isolated and purified by the immunomagnetic microbeads,then T cells were ac-tivated with anti-CD3/CD28 mAbs or alloantigen.The inhibitory effect of BD691 on activated T cell proliferation, the cytotoxic effect BD891 on resting T cells and the expression of activated T cells marker CD25 were measured by flow cytometry.Furthermore, ELISA was used to detect the secretion of cytokines associated with T cell differentiation. Results BD691 significantly inhibited the prolif-eration of T cells being stimulated by anti-CD3/CD28 mAb or alloantigen in a dose-dependent manner, and IC50 values are (8.5 ± 1.5)μmol/L and (7.2 ±1.3)μmol/L, respectively.However, BD691 had no obvious cytotoxic effects on resting T cells and periph-eral blood mononuclear cells, even at a high concentration ( up to 100μmol/L) .In T cells which were not activated by anti-CD3/CD28 mAb, the percentage of CD25+T cells is only 1.6%of the total cells, while the number increased to 68% after activating treatment.Mean-while, in T cells which were activated by 0, 3.3, 10, 30μmol/L BD691, no obvious change of CD25 expression were observed, while immunosuppressant FK506 (0.1μmol/L) significantly decreased the expression of CD25 +T cells (14.9%).In unactivated T cells, 95.6%cells were at G0/G1 phase, while after activation, the percentage of cells at G0/G1 phase reduced to 57.7%.In addition, BD691 inhibited the secretion of IFN-γ, IL-6 and IL-17 in activated T cells, but had no effects on the secretion of IL-2, IL-4 and IL-10. Co nclusion BD691 exerts no effects on T cell activation, but it inhibits T cell proliferation by inducing T cell cycling arrest at G0/G1 phase.Moreover, BD691 inhibits the secretion of key cytokines (such as IFN-γ, IL-6, IL-17) closely related to the differ-entiation of Th1 and Th17 cells.The results suggest that BD 691 is a potential lead compound to develop a new immunosuppressant for the inhibition of abnormal proliferation and differentiation of T cells.%目的: T细胞的异常增殖在自身免疫疾病的发生发展中起重要作用。文中探究小分子化合物BD691抑制T细胞增殖的机制。方法免疫磁珠纯化人外周血T细胞,anti-CD3/CD28抗体或同种异型抗原活化T细胞。流式细胞术检测BD691对活化T细胞的增殖抑制作用、静息T细胞的细胞毒性作用以及对T细胞活化标志CD25表达的影响,双抗夹心法酶联免疫吸附试验检测BD691对T细胞分化相关的细胞因子分泌的影响。结果 BD691抑制anti-CD3/CD28抗体或同种异型抗原刺激的T细胞增殖,IC50分别为(85.±1.5)、(7.2±1.3)μmol/L,BD691对人静息初始T细胞和人静息PBMC均无显著细胞毒性。在未经anti-CD3/CD28抗体活化的T细胞中,CD25+表达的细胞仅占细胞总数的1.6%,而活化后CD25+细胞比例增加到68.0%。同时,0、3.3、10、30μmol/LBD691处理活化的T细胞,却未观察到CD25的表达有明显的改变,而免疫抑制剂FK506(0.1μmol/L)则显著降低活化T细胞中CD25的表达(14.9%)。 T细胞活化后G0/G1期细胞比例为57.7%,当BD691作用于活化的 T细胞后此比例升高,呈剂量依赖效应。 BD691对IFN-γ、 IL-6和IL-17的抑制呈剂量依赖效应。结论BD691不影响T细胞活化,但通过阻滞细胞周期于G0/G1期抑制活化T细胞的增殖。 BD691对与Th1和Th17细胞分化密切相关的关键细胞因子IFN-γ、IL-6、IL-17有显著抑制作用,提示BD691有望作为先导化合物开发抑制T细胞异常增殖和分化的新型免疫抑制剂。
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号